AbbVie Inc (NYSE:ABBV)

98.48
Delayed Data
As of Jun 18
 -1.09 / -1.09%
Today’s Change
69.38
Today|||52-Week Range
125.86
+1.83%
Year-to-Date
Bristol-Myers Posts Data on Empliciti, China Approves Opdivo
Jun 18 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie
Jun 11 / Zacks.com - Paid Partner Content
AbbVie Declares Quarterly Dividend
Jun 17 / GuruFocus News - Paid Partner Content
Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant
Jun 08 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals
Jun 15 / Zacks.com - Paid Partner Content
Gilead Collaborates with Hookipa for HBV and HIV Therapies
Jun 06 / Zacks.com - Paid Partner Content
Analysts Remain Bullish on Flexion Therapeutics
Jun 12 / GuruFocus News - Paid Partner Content
Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive
Jun 06 / Zacks.com - Paid Partner Content
JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space
Jun 11 / Zacks.com - Paid Partner Content
ASCO Ends: Winners & Losers at the Key Cancer Research Event
Jun 06 / Zacks.com - Paid Partner Content
Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval
Jun 11 / Zacks.com - Paid Partner Content